# Editas Medicine (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/editas-medicine-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 29.5 |
| Citations | 50,625 |
| City | Cambridge |
| Country | US |
| Description | Editas Medicine (United States) is a research organisation in Cambridge, US. OpenAlex records 194 works and 50,625 citations for it. 130 researchers list it as their most recent affiliation. |
| Homepage | https://www.editasmedicine.com/ |
| OpenAlex ID | https://openalex.org/I4210129873 |
| Region | Massachusetts |
| Researchers | 130 |
| ROR ID | https://ror.org/03a00yh12 |
| Type | company |
| Works | 194 |

## University papers

- [Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://scholariq.org/papers/analysis-of-100-000-human-cancer-genomes-reveals-the-landscape-of-tumor/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Comparative Genomics Identifies a Flagellar and Basal Body Proteome that Includes the BBS5 Human Disease Gene](https://scholariq.org/papers/comparative-genomics-identifies-a-flagellar-and-basal-body-proteome-that/)
- [Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/establishing-guidelines-to-harmonize-tumor-mutational-burden-tmb-in-silico/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)
- [FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor](https://scholariq.org/papers/fgfr-genetic-alterations-predict-for-sensitivity-to-nvp-bgj398-a-selective-pan/)
- [Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population](https://scholariq.org/papers/genomic-context-of-ntrk1-2-3-fusion-positive-tumours-from-a-large-real-world/)
- [Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/aligning-tumor-mutational-burden-tmb-quantification-across-diagnostic-platforms/)

## University top topics

Showing 8 of 25.

- [CRISPR and Genetic Engineering](https://scholariq.org/topics/crispr-and-genetic-engineering/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)
- [Retinal Development and Disorders](https://scholariq.org/topics/retinal-development-and-disorders/)
- [Advanced biosensing and bioanalysis techniques](https://scholariq.org/topics/advanced-biosensing-and-bioanalysis-techniques/)
- [Prenatal Screening and Diagnostics](https://scholariq.org/topics/prenatal-screening-and-diagnostics/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.